Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease.

14 Mar 2005Baum L, Lam CW, Cheung SK, Kwok T, Lui V, Tsoh J, Lam L, Leung V, Hui E, Ng C, Woo J, Chiu HF, Goggins WB, Zee BC, Cheng KF, Fong CY, Wong A, Mok H, Chow MS, Ho PC, Ip SP, Ho CS, Yu XW, Lai CY, Chan MH, Szeto S, Chan IH, Mok V.

In a double-blind 6 month controlled trial conducted in 50+ year olds with memory decline, investigating 1 or 4g curcumin daily (against placebo).

Serum amyloid-beta pigmentation and isoprostanes did not differ between groups, although a non-significant trend was shown for serum levels of AB to rise.

Randomized Controlled Trial
1 effect
6 months
27 subjects

Reported Outcomes

DeterminantsOutcomeDetails

Curcumin (Turmeric) Herb risk & protective factor
Minor Protective Factor Curcumin (Turmeric)
Herb

Oxidative stress Lymphatic outcome
Minor decreased risk of Oxidative stress
Lymphatic system

Moderate evidence
-1.0%